Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02619669
Title Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/HER2- Breast Cancer
Recruitment Withdrawn
Gender female
Phase Phase I
Variant Requirements Yes
Sponsors Dartmouth-Hitchcock Medical Center
Indications

Her2-receptor negative breast cancer

Therapies

Sapanisertib

Letrozole

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST